Posts Tagged ‘Distribution Agreement’

ASX Company News: Traffic Technologies To Supply Road Lighting Products

Thursday, November 10th, 2011

Traffic Technologies Ltd (TTI) is pleased to announce that it has signed a supply agreement with Rexel Group Australia, under which TTI’s subsidiary Aldridge Traffic Systems will manufacture and supply a range of Road Lighting products for distribution and sale through Rexel’s branch network across Australia. TTI’s entry into the Road Lighting market represents a significant opportunity for the Group. It provides access to Australia’s Road Lighting market which is estimated to be worth up to $110m per year. It forms part of TTI’s strategy of expanding its activities in the growing Intelligent Transport Systems (“ITS”) sector, which involves the use of information and communication technology to manage traffic flows.

TTI’s Road Lighting business will be based at Aldridge’s offices in Rhodes NSW and will make use of TTI’s existing expertise in the development of technology for use in traffic management and will leverage off TTI’s existing customer base of State Road Authorities and contracting companies.

TTI operates through two divisions. The Company’s Traffic Products Division specialises in the design, manufacture and installation of traffic signals, emergency telephones and portable roadside technology along with a range of directional and regulatory traffic signs and traffic control products to road traffic authorities, municipal councils and construction companies. The Traffic Services Division provides equipment hire services to road traffic authorities and construction companies. Rexel Group Australia is a major player in the distribution of electrical parts and installation equipment. Rexel operates in all the States of Australia with 189 branches nationwide, 3 warehouses, a project office in each State and resources dedicated to supply a diversified range of products across Australia.

www.trafficltd.com.au

http://www.traderdealer.com.au/fundamentals/tti

Post to Twitter

ASX Company News: Phosphagenics Enters Asian Distribution Agreement

Wednesday, August 3rd, 2011

Melbourne biotechnology company Phosphagenics Limited (POH) has signed an agreement with a leading Asian distributor ensuring its Elixia® personal care range will be available in stores across the Asia Pacific region by the fourth quarter, 2011. The milestone distribution deal has been struck with the Sungate Supplies Pte Ltd, which will exclusively supply AS Watson and Company stores commencing in Singapore. A.S. Watson & Co. is a retail and consumer division of the Hong Kong based conglomerate Hutchison Whampoa Ltd, and over the past decade has become the  largest health and beauty retailer in the world with over 7,000 stores.

Announcing the agreement, Phosphagenics CEO, Dr Esra Ogru, said while the Elixia® ranges had recently achieved Australian sales target of $1 million, the Asian region “is the fastest growing skincare market in the world. In 2010 skincare sales across the region generated $37.4 billion,” she noted. “We are very excited about this milestone. This is in-line with our strategy to become an international skincare brand. We are continuing to pursue other opportunities in the Asia region as well as Europe and the US. Phosphagenics is on track to meet its stated goal of becoming financially independent by the end of 2012” said Dr Ogru.

Elixia® is an Australian owned and developed brand which includes anti-ageing skincare formulas, specially developed to penetrate and target fine lines and wrinkles. The active anti-ageing ingredients include SNAP-8, Carnosine and CoQ10. TPM® is a patented world first delivery technology which enables superior penetration of these active ingredients into the skin.

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products. The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

www.phosphagenics.com

www.elixia.com.au

http://www.traderdealer.com.au/fundamentals/poh

Post to Twitter

ASX Company News: AtCor Medical Enters Distribution Agreement With SunTech Medical

Thursday, July 28th, 2011

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, and SunTech Medical Inc., a leader in noninvasive blood pressure products and technologies, announced that they have entered into an exclusive, multi-year worldwide clinical trials distribution and data management agreement.

SunTech technology is especially well-suited for clinical trials, and features the patented OrbitTM blood pressure cuff, which is specifically designed for ambulatory wear, thus promoting patient comfort and compliance and improving data yield. This expansion of core lab services offers pharmaceutical companies, CRO’s and other researchers from a single source, greatly improved reliability and quality of information on the effects of drugs on central and peripheral hemodynamics-critically important data in identifying drug benefits as well as potential patient risk. AtCor Medical provides comprehensive trials support services: technology sales and leasing, trial site training, data quality assurance and best-in-class data management, using the AtCor WISDOM system. The WISDOM system allows real-time data quality assurance through secure, instantaneous transmission of data from the clinical trials site to AtCor’s data management center.

“We are delighted to be working with SunTech”, said Duncan Ross, AtCor Medical CEO. “This is an important addition to our portfolio. It will further enhance our relationship with key pharmaceutical customers and build on the strong business fundamentals we have established in the clinical trials market. With this new offering, clinical trials customers can choose from an expansive portfolio that includes noninvasive central blood pressure assessment, pulse wave velocity measurement, heart rate variability testing and ambulatory blood pressure monitoring, all backed by AtCor Medical’s best-in-class support services.”

For over twenty years, SunTech Medical has been the preeminent supplier of clinical grade blood pressure monitoring products and technologies. SunTech produces the leading cardiac stress test blood pressure monitor and is the world’s foremost manufacturer of ambulatory blood pressure monitoring (ABPM) products. SunTech Medical also offers solutions for in-office BP monitoring as well as a complete line of blood pressure cuffs designed for general and specific applications. AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively.

www.atcormedical.com

http://www.traderdealer.com.au/Fundamentals/acg

Post to Twitter

ASX Company News: Ceramic Fuel Cells Enters Netherlands

Friday, July 22nd, 2011

Ceramic Fuel Cells Limited (CFU), a leading developer of high efficiency and low emission power products for homes and other buildings, has signed a distribution agreement with Zestiq B.V., for Zestiq to market and sell Ceramic Fuel Cells’ BlueGen gas-to-electricity products in The Netherlands. Zestiq is part of the consortium of innovative companies which in March 2011 bought and installed a BlueGen in a 17th century canal house “De Groene Bocht” in the centre of Amsterdam. The aim of Zestiq is to accelerate ‘clean technology’ which is market ready. By developing smart business models for the different technologies, Zestiq aims to significantly reduce the time to mass market. Zestiq and its partners will market and sell BlueGen units to small commercial and residential customers in The Netherlands. The units will be installed and maintained by the service company of Eneco, Eneco Installatie Bedrijven.

The other members of the consortium include several leading energy companies in The Netherlands: Liander is a distribution company with 2.9 million electricity customers and 2.1 million gas customers. GasTerra is an international natural gas trading company owned by Royal Dutch Shell, Exxon Mobil and the Dutch Government. Responsibility for the planet and for society go hand in hand at GasTerra, which is why sustainability is an important component of GasTerra’s policy. The company supports the development of gas technologies, such as BlueGen units, that could make a significant contribution to the transition to sustainable sources of energy. A BlueGen unit is also installed at the home of a Director of GasTerra. The other consortium member, Eneco, currently provides services for a range of heating and cooling technologies, including other small scale combined heating and power products. Eneco invests in sustainable energy sources such as wind, hydro and solar energy, biomass, heating and cooling and decentralised, local generation of energy. Eneco is active in the North West European market with operations in Belgium, France, Germany and the United Kingdom. Eneco is mission partner of the World Wildlife Fund (WWF) and the world’s first energy company to participate in the international Climate Saver programme.

Matthijs Guichelaar from Zestiq said “Zestiq sees a huge market potential for BlueGen in the Netherlands. With its dense gas network, large gas reserves in the North and growing interest in distributed generation, we think the Netherlands and the BlueGen are a perfect match. We see great possibilities in carbon reduction and smartgrid applications. Together with Eneco we are looking forward to starting to make sales.”

Ceramic Fuel Cells Limited is a world leader in developing fuel cell technology to provide highly efficient and low-emission electricity from widely available natural gas. Ceramic Fuel Cells is developing fully integrated power and heating products with leading energy companies E.ON UK in the United Kingdom, GdF Suez in France and EWE in Germany.

www.cfcl.com.au

http://www.traderdealer.com.au/fundamentals/cfu

Post to Twitter

ASX Company News: Phosphagenics Enters Asian Distribution Agreement

Thursday, July 7th, 2011

Phosphagenics Limited (POH) has signed an agreement with a leading Asian distributor ensuring its Elixia personal care range will be available in stores across the ® Asia Pacific region by the fourth quarter, 2011. The milestone distribution deal has been struck with the Sungate Supplies Pte Ltd, which will exclusively supply AS Watson and Company stores commencing in Singapore. A.S. Watson & Co. is a retail and consumer division of the Hong Kong based conglomerate Hutchison Whampoa Ltd, and over the past decade has become the largest health and beauty retailer in the world with over 7,000 stores.

Announcing the agreement, Phosphagenics CEO, Dr Esra Ogru, said while the Elixia ® ranges had recently achieved Australian sales target of $1 million, the Asian region “is the fastest growing skincare market in the world.   In 2010 skincare sales across the region generated $37.4 billion,” she noted. “We are very excited about this milestone.  This is in-line with our strategy to become an international skincare brand.  We are continuing to pursue other opportunities in the Asia region as well as Europe and the US.  Phosphagenics is on track to meet its stated goal of becoming financially independent by the end of 2012” said Dr Ogru.  Cathy Yeap, the Managing Director of AS Watson, Singapore said “We are very excited to be involved in the Asian launch of Elixia® through our stores and we anticipate that we will replicate the very successful launch of the products in Australia.”

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology.  TPM® is a patient friendly and cost effective system used to deliver proven

pharmaceutical and nutraceutical products. The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

www.phosphagenics.com

www.elixia.com.au

http://www.traderdealer.com.au/fundamentals/poh

Post to Twitter

ASX Company News: Wasabi Energy Licenses New Technology

Tuesday, June 21st, 2011

Wasabi Energy (WAS) has signed a global Kalina Cycle®1 technology licensing agreement with FLSmidth , a leading supplier of engineering, procurement and construction (EPC) services to the global cement and minerals industries. This license agreement will facilitate the rapid adoption of the Kalina Cycle® across the global cement and lime manufacturing industry resulting in significant reductions in CO2 emissions for the cement industry whilst generating substantial licensing and engineering revenues for Wasabi Energy. FLSmidth has been granted a technology license by Wasabi Energy for the exclusive utilisation of the Kalina Cycle® technology across the global cement and lime manufacturing industry.  The license covers all aspects related to cement and lime manufacturing industry globally, with the exception of the countries covered by existing licensees.

FLSmidth have paid Wasabi Energy an upfront fee to secure exclusive access to the Kalina Cycle® technology in the cement and lime manufacturing industry. The Kalina Cycle® technology licensing fee incorporates specialised technology related training and technology transfer elements, initially for over 20 engineers. Wasabi Energy will receive technology royalties from FLSmidth for every newly installed Kalina Cycle® plant for the global cement and lime manufacturing industry.  Wasabi Energy has agreed to provide project engineering and commissioning support for an initial four projects to ensure the Kalina Cycle® technology is implemented optimally.

Executive Chairman of Wasabi Energy and Director of Global Geothermal Limited, Mr. John Byrne commented: “The negotiation of a global Kalina Cycle® technology licensing agreement with FLSmidth less than 5 months after the award of the landmark Khairpur Kalina Cycle® contract, highlights the confidence established market leaders like FLSmidth, see in the future of our waste-heat-to-power generation technology.”

Wasabi Energy holds a strategic investment in can be found in this section.  It has major investments in three key strategic assets. It owns 100% of the Kalina Cycle® power generation technology which utilises low grade, waste heat from industrial facilities or geothermal sources to produce electricity. It also owns a 17% interest in Australian Renewable Fuels, a separately ASX listed company (ARW) which produces liquid biofuels from a variety of non-food grade feedstocks.  Global Geothermal Limited (GGL) holds an extensive Kalina Cycle® intellectual property portfolio and is focused on licensing the innovative technology into two core business streams, Enhanced Energy Efficiency (EEE) and Renewable Energy Generation (REG).

www.wasabienergy.com

www.globalgeothermal.com

http://www.traderdealer.com.au/fundamentals/was

Post to Twitter

ASX Company News: GRG International Enters US Distribution Agreements

Tuesday, May 31st, 2011

ATM company GRG International Limited (GRG) has entered into agreements with two new US distribution partners; ValueTec Financial Equipment LLC and American Bank Equipment. Both will provide regional sales and support coverage for GRG ATMs and related banking products. The exclusive agreement with ValueTec Financial Equipment LLC gives GRG ATM sales, marketing and service rights to Valutec in Arizona, Colorado and Wyoming. ValueTec has more than 20 years of financial equipment experience and has sold ATM products to more than 500 financial institutions across seven states. The exclusive agreement with American Bank Equipment gives GRG coverage to American Bank Equipment in Missouri, Kentucky and Ohio. American Bank Equipment has a trusted reputation for sales and service of financial equipment throughout the world and has a large inventory and knowledgeable team of technicians.

GRG International is in a partnership between Global Cash Services and GRG Banking of Guangzhou, the largest ATM manufacturer in China. GRG International was founded to distribute GRG Banking products in the main English-speaking markets. GRG Banking is the largest ATM manufacturer in China, one of the largest ATM suppliers in the Asian region and is listed on the Shenzhen Stock Exchange with a $A2.2billion market capitalisation. The company leverages GRG Banking’s resources to design, develop, manufacture and sell ATMs, ATM management software and spare parts without incurring the associated overheads. GRG International will also sell the comprehensive range of other GRG Banking products such as Recyclers, Teller Cash Dispenser, Automatic Depository and Kiosk products. GRG International has exclusive rights to distribute GRG ATMs in the United States, Canada, Australia, United Kingdom and Ireland and non exclusive rights to the Mexican, South African and Indian markets.

www.grgatm.com

http://www.traderdealer.com.au/fundamentals/grg

Post to Twitter

ASX Company News: Motopia Enters Distribution Contract With Educate

Tuesday, May 31st, 2011

Mobile technology company Motopia (MOT) is delighted to announce it has signed a heads of agreement with Educate Ltd for exclusive distribution of the Lemon and Lime Platform to colleges and universities in the United Kingdom. Lemon and Lime is a revolutionary ready-made mobile application solution targeted at event organisers that can now be used to enhance the experience of students attending university all around the world. Customers in Australia already using Lemon and Lime apps include Future Music Festival, Fuzzy Events, Sydney Fringe Festival, Summadayze festival, WOMAdelaide and Adelaide Casino. Lemon and Lime has now been further developed to suit the needs of tertiary institutions around the world, and includes functionality to engage with students and enhance their connection with the university.

Students can benefit from linking with points of interest on campus, downloading interactive maps, having convenient information on course timetables, being updated with university event schedules and being offered university-controlled social media integration to enable them to share their experiences. Educate Ltd currently supplies its clients with advertising and media solutions and is in the perfect position to distribute this unique ready-made App solution to its existing client base of more than 120 universities across the UK.

Dan Beynon, commercial director of Educate Ltd, is excited to be joining forces with Motopia. “This partnership with Motopia represents a considerable opportunity for Educate Ltd and is a perfect extension that allows us to grow our product offering to universities with a best of breed mobile applications platform and take advantage of the phenomenal growth in the mobile marketplace,’’ he said.

Motopia is a publicly-listed global company that specialises in mobile and digital marketing, creating applications and content for use on mobile phones and other online devices. Motopia aims to become a world leader in mobile marketing, platform development and branded mobile content creation, licensing and distribution. Motopia has offices around the world, including in Melbourne, Adelaide, Singapore, London and Los Angeles.

www.motopia.com

http://www.traderdealer.com.au/fundamentals/mot

Post to Twitter

ASX Company News: KarmelSonix Expands Distribution To France and Nordic Region

Friday, November 12th, 2010

KarmelSonix Limited (KSX) is pleased to announce the expansion of its distribution partner network throughout the Nordic Region and France.

In France, the Company has appointed Belateam SAS, a member of the Santeol Group, as its partner for all of France. The Belateam group has extensive experience in the respiratory and sleep field, offering healthcare solutions in the diagnosis, treatment and monitoring of patients suffering with conditions such as asthma, sleep disordered breathing and chronic obstructive pulmonary disease (COPD).Today Belateam SAS supplies CPAP, non-invasive ventilation and oxygen to the French marketplace. With this broad range of respiratory products currently being sold, the KarmelSonix technology dovetails perfectly into this respiratory portfolio.

In France, approximately 7% of the population suffers from some form of asthma. This equates to 3.5 million people.

The focus for the Belateam group will be to sell the PulmoTrack into the hospital environment, and the WheezoMeterTM into both the private patient market and doctor’s surgeries. The Belateam group in conjunction with KSX will be developing and implementing a continuous revenue model for the ambulatory monitoring device, the WHolterTM. The WHolterTM allows the physician to obtain data relating to wheeze detection, cough detection, and respiratory rate in the patient’s home environment.

In a further expansion to the Company’s global presence, the following distributors have been appointed in the Nordic region: Maribo Medica in Denmark, Somnivest in Sweden and Spira OY in Finland

Maribo Medica specialises in equipment for the diagnosis and treatment of respiratory conditions including sleep apnea, COPD, and ALS. The Company commenced operations in 1996 and currently has a clientele that includes most of the country’s hospitals as well as lung and sleep clinics. Maribo Medica represents major companies in Denmark, including ResMed and Embla. Somnivest in Sweden also has specialist expertise in the respiratory field. Spira OY of Finland is a leader in its field providing service and products in areas directly related to the KarmelSonix products such as lung function testing, sleep apnea, oxygen therapy and critical care.

KSX Managing Director for Europe and Asia Pacific, Paul Eisen said “Partnering with Belateam SAS now gives us access to France, one of the largest potential markets in Europe for KSX, with over 3.5 million people suffering from Asthma, and at least that number again suffering with Chronic Obstructive Pulmonary Disease (COPD). In relation to the Nordic region, the Company is delighted to have 3 partners with substantial, long term expertise in the respiratory field in their respective countries. All have excellent access to the pulmonologists and leading hospital clinics in their countries”.

Importantly, KarmelSonix now has secured European distribution coverage in most major markets, including UK, France, Germany, Italy, Nordics, Netherlands, Belgium, Czech Republic, Lithuania, Latvia, Greece and Romania.

www.karmelsonix.com

http://www.traderdealer.com.au/Fundamentals/ksx

Post to Twitter

ASX Company News: Imugene To Commercialise Animal Vaccines

Thursday, October 14th, 2010

Imugene Limited (IMU) announced that it has signed a global agreement with one of the world’s leading animal health companies to commercialise its vaccines for pigs and poultry. The agreement signed with Novartis Animal Health, a business unit within the global Novartis Group, gives the company exclusive global rights to all of Imugene’s technologies and intellectual properties, including its vaccines and productivity enhancers. Novartis will pay the costs of developing products, and Imugene will receive an initial payment as well as milestone payments and royalties on product sales.

Dr Warwick Lamb, CEO of Imugene said “We are pleased to have executed an agreement with Novartis, a top international animal health company. “This is a very good outcome for Imugene and its shareholders and lays the foundation for a fruitful, long term partnership. We are looking forward to working with Novartis to progress our technology through evaluation and product development to sales.”

Imugene Limited (IMU) specialises in the development and commercialisation of novel animal health products for pigs and poultry. Imugene is developing a range of biologically based vaccines for pigs and poultry, which are safer and easier to use than chemical based products. Imugene’s business model is to maximise income from the receipt of research fees, license and royalty income from an alliance partner with sufficient expertise and infrastructure to develop, market and exploit the Imugene range of vector vaccines.

www.imugene.com

http://www.traderdealer.com.au/Fundamentals/imu

Post to Twitter